Midatech Pharma plc Retained Earnings 2011-2026 | MTP

Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.

Possible uses include

reinvestment in development (R&D, equipment, marketing)
debt repayment
acquisition of other companies
creation of reserves for the future

A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.

The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.

Annual Retained Earnings Midatech Pharma plc

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	-	-	-122 M	-99.8 M	-89.7 M	-74.7 M	-59.1 M	-39.2 M	-27.8 M	-20.4 M	-	-

All numbers in GBP currency

Indicator range from annual reports

Maximum	Minimum	Average
-20.4 M	-122 M	-66.6 M

Quarterly Retained Earnings Midatech Pharma plc

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-128 M	-	-	-	-122 M	-	-	-	-99.8 M	-	-	-	-89.7 M	-	-	-	-74.7 M	-	-	-	-59.1 M	-	-	-	-39.2 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in GBP currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
-39.2 M	-128 M	-87.5 M

Retained Earnings of other stocks in the Biotechnology industry

Issuer	Retained Earnings	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-158 M	-	2.43 %	$ 254 M	Germany
Aligos Therapeutics ALGS	-642 M	$ 8.48	6.0 %	$ 83.8 M	USA
Alterity Therapeutics Limited ATHE	-182 M	$ 3.66	-1.48 %	$ 8.81 B	Australia
I-Mab IMAB	-8.33 B	-	-	$ 866 M	China
AlloVir ALVR	-160 M	-	4.14 %	$ 49.1 M	USA
Applied Molecular Transport AMTI	-366 M	-	-	$ 10.1 M	USA
Alexion Pharmaceuticals, Inc. ALXN	5.24 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	-405 M	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	-17.1 M	-	-13.47 %	$ 169 M	France
Esperion Therapeutics ESPR	-1.62 B	$ 2.19	0.92 %	$ 455 M	USA
Evogene Ltd. EVGN	-179 M	$ 0.78	-4.39 %	$ 27.9 M	Israel
Applied Therapeutics APLT	-469 M	-	-	$ 8.42 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	-108 M	-	-1.52 %	$ 24.7 M	USA
Genmab A/S GMAB	7.11 B	$ 28.2	-0.18 %	$ 18 B	Danmark
Grifols, S.A. GRFS	619 M	$ 8.38	2.01 %	$ 6.83 B	Spain
GT Biopharma GTBP	-724 M	$ 0.38	2.47 %	$ 2.1 M	USA
Amphastar Pharmaceuticals AMPH	667 M	$ 21.28	4.44 %	$ 995 M	USA
Halozyme Therapeutics HALO	54.8 M	$ 66.92	-1.33 %	$ 8.02 B	USA
Acorda Therapeutics ACOR	-1.19 B	-	-24.86 %	$ 820 K	USA
Институт стволовых клеток человека ISKJ	69.4 M	-	-	-	Russia
Adverum Biotechnologies ADVM	-1.07 B	-	-	$ 86.2 M	USA
Harmony Biosciences Holdings HRMY	161 M	$ 29.05	0.55 %	$ 1.67 B	USA
Advaxis ADXS	-197 M	-	-9.65 %	$ 45.9 M	USA
Aeterna Zentaris AEZS	-335 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	-63.5 M	-	-10.17 %	$ 12.2 K	USA
Incyte Corporation INCY	214 M	$ 95.33	-0.77 %	$ 18.6 B	USA
Aeglea BioTherapeutics AGLE	-1.13 B	-	-	$ 1.01 B	USA
Akebia Therapeutics AKBA	-1.68 B	$ 1.46	4.29 %	$ 375 M	USA
Applied Genetic Technologies Corporation AGTC	-308 M	-	-	$ 26.5 M	USA
Allakos ALLK	-1.12 B	-	-	$ 28.6 M	USA
Can-Fite BioPharma Ltd. CANF	-176 M	$ 2.99	2.4 %	$ 4.92 M	Israel
Aptinyx APTX	-353 M	-	-39.0 %	$ 4.57 M	USA
Aquestive Therapeutics AQST	-447 M	$ 4.2	2.82 %	$ 449 M	USA
Aravive ARAV	-616 M	-	-13.39 %	$ 1.45 M	USA
Arcutis Biotherapeutics ARQT	-1.14 B	$ 24.24	0.1 %	$ 3.08 B	USA
Innate Pharma S.A. IPHA	-220 M	$ 1.47	4.26 %	$ 235 M	France
AIkido Pharma AIKI	-268 M	-	1.93 %	$ 17.4 M	USA
Celldex Therapeutics CLDX	-1.81 B	$ 32.59	1.09 %	$ 2.16 B	USA
Autolus Therapeutics plc AUTL	-1.39 B	$ 1.48	-0.67 %	$ 394 M	Britain
Aptose Biosciences APTO	-566 M	-	-45.71 %	$ 1.2 M	Canada
Cidara Therapeutics CDTX	-611 M	-	-	$ 1.41 B	USA
AVROBIO AVRO	-477 M	-	1083.1 %	$ 745 M	USA
Ayala Pharmaceuticals AYLA	-149 M	-	-	$ 7.46 M	Israel
AstraZeneca PLC AZN	5.3 B	-	-	$ 96.9 B	Britain
Akero Therapeutics AKRO	-826 M	-	-	$ 3.67 B	USA
CureVac N.V. CVAC	-1.06 B	-	-	$ 867 M	Germany
Brainstorm Cell Therapeutics BCLI	-237 M	-	-2.5 %	$ 5.88 M	USA
BeiGene, Ltd. BGNE	-8.32 B	-	0.49 %	$ 251 B	Cayman-islands